Literature DB >> 16888096

Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.

Linfeng Chen1, Przemyslaw Juszczynski, Kunihiko Takeyama, Ricardo C T Aguiar, Margaret A Shipp.   

Abstract

The strength and duration of B-cell-receptor (BCR) signaling depends upon the balance between protein tyrosine kinase (PTK) activation and protein tyrosine phosphatase (PTP) inhibition. BCR-dependent activation of the SYK PTK initiates downstream signaling events and amplifies the original BCR signal. Although BCR-associated SYK phosphorylation is clearly regulated by PTPs, SYK has not been identified as a direct PTP substrate. Herein, we demonstrate that SYK is a major substrate of a tissue-specific and developmentally regulated PTP, PTP receptor-type O truncated (PTPROt). PTPROt is a member of the PTPRO family (also designated GLEPP, PTP-Ø, PTP-oc, and PTPu2), a group of highly conserved receptor-type PTPs that are thought to function as tumor suppressor genes. The overexpression of PTPROt inhibited BCR-triggered SYK tyrosyl phosphorylation, activation of the associated adaptor proteins SHC and BLNK, and downstream signaling events, including calcium mobilization and mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) activation. PTPROt overexpression also inhibited lymphoma cell proliferation and induced apoptosis in the absence of BCR cross-linking, suggesting that the phosphatase modulates tonic BCR signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16888096     DOI: 10.1182/blood-2006-03-013821

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Influence of 6q22-23 on overall survival in primary central nervous system lymphoma. Analysis of North Central Cancer Treatment Group trials 86 72 52, 93 73 51 and 96 73 51.

Authors:  Ellen R McPhail; Mark E Law; Paul A Decker; Brian P O'Neill
Journal:  Br J Haematol       Date:  2011-01-31       Impact factor: 6.998

Review 2.  The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.

Authors:  Vaishalee P Kenkre; Brad S Kahl
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

3.  AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.

Authors:  Tasneem Motiwala; Nicola Zanesi; Jharna Datta; Satavisha Roy; Huban Kutay; Allyn M Checovich; Mohamed Kaou; Yiming Zhong; Amy J Johnson; David M Lucas; Nyla A Heerema; John Hagan; Xiaokui Mo; David Jarjoura; John C Byrd; Carlo M Croce; Samson T Jacob
Journal:  Blood       Date:  2011-10-14       Impact factor: 22.113

4.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.

Authors:  Andrew L Feldman; Ahmet Dogan; David I Smith; Mark E Law; Stephen M Ansell; Sarah H Johnson; Julie C Porcher; Nazan Ozsan; Eric D Wieben; Bruce W Eckloff; George Vasmatzis
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

5.  GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.

Authors:  Rosanna Pescini Gobert; Monique van den Eijnden; Cedric Szyndralewiez; Catherine Jorand-Lebrun; Dominique Swinnen; Linfeng Chen; Corine Gillieron; Fiona Pixley; Pierre Juillard; Patrick Gerber; Caroline Johnson-Léger; Serge Halazy; Montserrat Camps; Agnes Bombrun; Margaret Shipp; Pierre-Alain Vitte; Vittoria Ardissone; Chiara Ferrandi; Dominique Perrin; Christian Rommel; Rob Hooft van Huijsduijnen
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

6.  The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.

Authors:  Stephen E Spurgeon; Greg Coffey; Luke B Fletcher; Russell Burke; Jeffrey W Tyner; Brian J Druker; Andreas Betz; Francis DeGuzman; Yvonne Pak; Dale Baker; Anjali Pandey; Stanley J Hollenbach; Uma Sinha; Marc M Loriaux
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

7.  Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines.

Authors:  R A Wilcox; D X Sun; A Novak; A Dogan; S M Ansell; A L Feldman
Journal:  Leukemia       Date:  2009-09-24       Impact factor: 11.528

8.  PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.

Authors:  Tasneem Motiwala; Sarmila Majumder; Kalpana Ghoshal; Huban Kutay; Jharna Datta; Satavisha Roy; David M Lucas; Samson T Jacob
Journal:  J Biol Chem       Date:  2008-11-07       Impact factor: 5.157

9.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Jonathan W Friedberg; Jeff Sharman; John Sweetenham; Patrick B Johnston; Julie M Vose; Ann Lacasce; Julia Schaefer-Cutillo; Sven De Vos; Rajni Sinha; John P Leonard; Larry D Cripe; Stephanie A Gregory; Michael P Sterba; Ann M Lowe; Ronald Levy; Margaret A Shipp
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

10.  Methylation of the PTPRO gene in human hepatocellular carcinoma and identification of VCP as its substrate.

Authors:  Shu-hao Hsu; Tasneem Motiwala; Satavisha Roy; Rainer Claus; Mufaddal Mustafa; Christoph Plass; Michael A Freitas; Kalpana Ghoshal; Samson T Jacob
Journal:  J Cell Biochem       Date:  2013-08       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.